Enlivex Announces Peer-Reviewed Publication In Frontiers In Immunology Of Clinical Data Details Resolution Of Acute Respiratory Distress Syndrome From Two Phase I/II Trials Evaluating Allocetra In Patients With COVID-19
Portfolio Pulse from Happy Mohamed
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) has announced the publication of clinical data from two Phase I/II trials evaluating Allocetra in patients with COVID-19. The data, published in Frontiers in Immunology, shows a robust safety profile and significant improvements in mortality in 21 Allocetra-treated patients compared to matched historical controls. The company believes that Allocetra could potentially become a leading therapy for ARDS patients.
August 04, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the Phase I/II trials of Allocetra could potentially boost investor confidence in Enlivex Therapeutics, leading to a positive impact on the company's stock price in the short term.
The positive results from the trials, including a robust safety profile and significant improvements in mortality, could be seen as a strong validation of Allocetra's potential. This could lead to increased investor interest in Enlivex, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100